S6/10Social
AstraZeneca's Rare Drug Trial Failure Sends Shares Plunging
AstraZeneca Plc's shares dropped more than 10% after a trial of a new heart drug failed to help prevent heart problems in patients with a rare disease. Bloomberg Intelligence's Sam Fazeli has more on "Bloomberg Open Interest." (Source: Bloomberg)
⚠️ A model estimate of cascade risk — not a guarantee and not buy/sell. Calibration uses resolved outcomes only; monitor confirmation indicators below.
A
Эскалация— 25% model probability
Forecast derived from cascade analysis. Watch confirmation indicators below.
Horizon: 7–30 days